Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21806795 | 0.79 | LMNA (0.37) | TDP1LMNAL3MBTL1PDE4AAPP | |
| SCHEMBL1670192 | 0.79 | LMNA (0.37) | TDP1LMNAL3MBTL1PDE4AAPP | |
| SCHEMBL4621765 | 0.75 | USP2 (0.44) | TDP1LMNAL3MBTL1KDM4EUSP2 | |
| SCHEMBL5573408 | 0.73 | TDP1 (0.55) | TDP1LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL28278210 | 0.73 | TDP1 (0.55) | TDP1LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL28256211 | 0.70 | TDP1 (0.50) | TDP1LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL252338 | 0.70 | TDP1 (0.50) | TDP1LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL5683104 | 0.68 | TDP1 (0.48) | TDP1LMNAL3MBTL1KDM4EPDE4A | |
| Mannitol SCHEMBL28766951 | 0.67 | LMNA (0.61) | TDP1LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL8641932 | 0.67 | TDP1 (0.52) | TDP1LMNAL3MBTL1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4327867-A2 | PHARMACEUTICAL COMPOSITION COMPRISING GLUCOPYRANOSYL DIPHENYLMETHANE DERIVATIVES, PHARMACEUTICAL DOSAGE FORM THEREOF, PROCESS FOR THEIR PREPARATION AND USES THEREOF FOR IMPROVED GLYCEMIC CONTROL IN A PATIENT | Boehringer Ingelheim International GmbH (DE) | 2024-02-28 | — | — | EP | disclosed |
| EP-2395968-B1 | PHARMACEUTICAL COMPOSITION COMPRISING GLUCOPYRANOSYL DIPHENYLMETHANE DERIVATIVES, PHARMACEUTICAL DOSAGE FORM THEREOF, PROCESS FOR THEIR PREPARATION AND USES THEREOF FOR IMPROVED GLYCEMIC CONTROL IN A PATIENT | BOEHRINGER INGELHEIM INT (DE) | 2024-01-17 | — | — | EP | disclosed |
| US-20220211725-A1 | Pharmaceutical Composition Comprising Venetoclax | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2022-07-07 | — | — | US | disclosed |
| US-20220193045-A1 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2022-06-23 | — | — | US | disclosed |
| US-20210283156-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2021-09-16 | — | — | US | disclosed |
| EP-3854404-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2021-07-28 | — | — | EP | disclosed |
| EP-2729151-B1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2021-03-31 | — | — | EP | disclosed |
| US-20200268777-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2020-08-27 | — | — | US | disclosed |
| US-20200188337-A1 | Pharmaceutical composition and pharmaceutical dosage form comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof | BOEHRINGER INGELHEIM INT (DE) | 2020-06-18 | — | — | US | disclosed |
| US-10603292-B2 | Pharmaceutical composition and pharmaceutical dosage form comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-03-31 | — | — | US | disclosed |
| EP-2396005-A1 | SGLT-2 INHIBITOR FOR TREATING TYPE 1 DIABETES MELLITUS, TYPE 2 DIABETE MELLITUS, IMPAIRED GLUCOSE TOLERANCE OR HYPERGLYCEMIA | Boehringer Ingelheim International GmbH (DE) | 2011-12-21 | — | — | EP | disclosed |
| EP-2252270-A2 | FORMULATIONS OF FLIBANSERIN | Boehringer Ingelheim International GmbH (DE) | 2010-11-24 | — | — | EP | disclosed |
| WO-2010092123-A1 | SGLT-2 INHIBITOR FOR TREATING TYPE 1 DIABETES MELLITUS, TYPE 2 DIABETE MELLITUS, IMPAIRED GLUCOSE TOLERANCE OR HYPERGLYCEMIA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010092126-A1 | PHARMACEUTICAL COMPOSITION COMPRISING GLUCOPYRANOSYL DIPHENYLMETHANE DERIVATIVES, PHARMACEUTICAL DOSAGE FORM THEREOF, PROCESS FOR THEIR PREPARATION AND USES THEREOF FOR IMPROVED GLYCEMIC CONTROL IN A PATIENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010070023-A2 | FORMULATIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-24 | — | — | WO | disclosed |
| WO-2009100886-A2 | FORMULATIONS OF FLIBANSERIN | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-20 | — | — | WO | disclosed |
| EP-2090297-A1 | Formulations of flibanserin | Boehringer Ingelheim International GmbH (DE) | 2009-08-19 | — | — | EP | disclosed |
| EP-2054041-A2 | FORMULATIONS OF FLIBANSERIN AND METHOD FOR MANUFACTURING THE SAME | Boehringer Ingelheim International GmbH (DE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008019996-A2 | FORMULATIONS OF FLIBANSERIN AND METHOD FOR MANUFACTURING THE SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | WO | disclosed |
| US-20080038347-A1 | Extended release tablet formulations of flibanserin and method for manufacturing the same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200188337-A1 | Pharmaceutical composition and pharmaceutical dosage form comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof | AFF2, FLNB, AFF1 | TDP1 1622/4885LMNA 1189/4885L3MBTL1 4793/4885 |
| US-20200268777-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | SLC5A2, SLC5A1, SLC2A2 | TDP1 4394/4885LMNA 3438/4885L3MBTL1 4453/4885 |
| US-10603292-B2 | Pharmaceutical composition and pharmaceutical dosage form comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof | AFF2, FLNB, AFF1 | TDP1 1622/4885LMNA 1189/4885L3MBTL1 4793/4885 |
| US-20210283156-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | TDP1 2161/4885LMNA 3460/4885L3MBTL1 4173/4885 |
| US-20220193045-A1 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF | SLC5A2, SLC5A1, SLC2A2 | TDP1 4577/4885LMNA 3484/4885L3MBTL1 4861/4885 |
| US-20220211725-A1 | Pharmaceutical Composition Comprising Venetoclax | U2AF1, SF3B1, SF3B3 | TDP1 151/4885LMNA 1526/4885L3MBTL1 4431/4885 |
| US-20080038347-A1 | Extended release tablet formulations of flibanserin and method for manufacturing the same | FLNB, FFAR3, FFAR4 | TDP1 4139/4885LMNA 781/4885L3MBTL1 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.